Method of measuring cancer aggressiveness and detection thereof
OwnerIgor Ivakhnenko, Alexander Balyurainventors
Life of this patent
Estimating the term…
Loading patent…
OwnerIgor Ivakhnenko, Alexander Balyurainventors
Estimating the term…
Erythrocyte sedimentation rate (“ESR”) determinations of a patient's blood that has been combined either with blood serum from pregnant mammals or with fetal embryonic serum yield measurable results correlating well with the presence of an on-going cancer. This cancer detection method is based on differential ESR determinations and uses paired in vitro ESR tests, in which a patient's whole blood is combined with a control serum (in a control vial) comprising serum from non-pregnant mammal and with a test serum (in a test vial) comprising either fetal embryonic serum or serum from a pregnant mammal to measure differential ESR in the tested control vials. Cancer coefficient K is calculated based on the ESR measurements and is compared with a threshold value to determine whether the patient may be identified as possibly having an on-going malignancy. A kit for performing the cancer screening methodology is also provided.
A method of cancer detection in a patient, comprising the steps of:
A method for detecting a malignancy in a patient, comprising:
A method for detecting a malignancy in a patient, comprising the steps of:
Dependencies are inferred from the claim text.